Novartis has doubled down on its gene therapy collaboration with Voyager Therapeutics, stumping up another $1.2 billion-plus in potential milestone payments and directing the partnership at two new neurological diseases.The new agreement, which includes another $100 million payment to Voyager, extends a 2022 alliance that included a $54 million upfront fee and up to $1.7 […]
